RECRUITINGOBSERVATIONAL
Chemotherapy Induced Neuropathy in Cancer Patients
Evaluation of Chemotherapy Induced Neuropathy in Solid Cancer Patients
About This Trial
The purpose of this prospective study is to perform Nerve conduction test, Vitamin D, Vitamin B12 and NADPH oxidase 4(NOX4) expression to assess severity of chemotherapy induced Peripheral neuropathy (CIPN) in solid cancer (Head and Neck, Breast, Prostate) patients who planned for at least 4 cycle of chemotherapy in different nutrient status level and gene expression.
Who May Be Eligible (Plain English)
Who May Qualify:
- All patients receiving chemotherapy for solid cancer
- Patient aged\>18years
Who Should NOT Join This Trial:
- Age ≤ 18 years
- Pre-existing neuropathy
- Patients diagnosed with Psychiatric illness
- Patients with pre-existing peripheral neuropathy
- Patients taking medication for neuropathy
- Long standing diabetes (\>10 years)
- Renal and Hepatic disease
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* All patients receiving chemotherapy for solid cancer
* Patient aged\>18years
Exclusion Criteria:
* Age ≤ 18 years
* Pre-existing neuropathy
* Patients diagnosed with Psychiatric illness
* Patients with pre-existing peripheral neuropathy
* Patients taking medication for neuropathy
* Long standing diabetes (\>10 years)
* Renal and Hepatic disease
Treatments Being Tested
DRUG
Cisplatin, Carboplatin, Paclitaxel, Docetaxel
Solid cancer Patients receiving any one drug or in combination
Locations (1)
Himalayan Hospital(Cancer Research Institute), Himalayan Institute of Medical Sciences
Dehradun, India